Primitive neuroectodermal tumor of the kidney at the advanced stage: A case series of eight Chinese patients

Sun,Qipeng; Miao,Bin; Lao,Xiangming; Yuan,Ping; Cai,Jiarong; Zhan,Hailun

doi:10.3892/mco.2018.1611

Primitive neuroectodermal tumor of the kidney at the advanced stage: A case series of eight Chinese patients

Authors:
- Qipeng Sun
- Bin Miao
- Xiangming Lao
- Ping Yuan
- Jiarong Cai
- Hailun Zhan
View Affiliations

Affiliations: Department of Urology, Lingnan Hospital, The Third Affiliated Hospital, Sun Yat‑sen University, Guangzhou, Guangdong 510530, P.R. China, Department of Renal Transplantation, Lingnan Hospital, The Third Affiliated Hospital, Sun Yat‑sen University, Guangzhou, Guangdong 510530, P.R. China, Department of Hepatobiliary Surgery, Cancer Center, Sun Yat‑sen University, Guangzhou, Guangdong 510060, P.R. China, Department of Obstetrics and Gynecology, IVF Center, Sun Yat‑sen Memorial Hospital, Sun Yat‑sen University, Guangzhou, Guangdong 510120, P.R. China, Department of Urology, Lingnan Hospital, The Third Affiliated Hospital, Sun Yat‑sen University, Guangzhou, Guangdong 510530, P.R. China
Published online on: April 19, 2018 https://doi.org/10.3892/mco.2018.1611
Pages: 743-748

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Primitive neuroectodermal tumor (PNET) rarely occurs as a primary renal neoplasm. Renal (r)PNET is a rare but aggressive neoplasm with poor prognosis; the majority of patients are diagnosed as advanced stage at presentation and face a worse prognosis than patients with localized disease. The present study describes the diagnosis and management of eight cases of rPNET at an advanced stage, who were treated at two institutions [Lingnan Hospital (branch of The Third Affiliated Hospital) and the Cancer Center of Sun Yat‑sen University, Guangzhou], from December 2004 to January 2013. The clinical and pathological results of all patients were retrospectively obtained. Kaplan‑Meier analysis was performed to estimate patient survival. The study cohort comprised five males and three females. Radical nephrectomy was performed in seven cases, while the remaining case only received needle biopsy of the tumor. Five cases received adjuvant chemotherapy, while three received no further treatment after surgery. Of note, one case received cytokine‑induced killer (CIK) cell immunotherapy combined with surgery and chemotherapy. The overall median survival was 20 months with a 3‑year survival rate of 25%. The overall survival of the four patients who received adjuvant chemotherapy following surgery was 36 months, compared with 10 months in the three patients without further treatment. The patient who received CIK cell immunotherapy survived for 20 months. Based on the observations of the present and previous studies, surgical excision and chemotherapy are recommended for treating rPNET at advanced stage. Furthermore, the present study was the first to report on CIK cell immunotherapy for a patient with rPNET, indicating that it may be a promising optional treatment. However, further studies are required to validate the benefit of CIK cells and to establish an appropriate immunotherapy protocol.

View Figures

View References

1	de Alava E and Gerald WL: Molecular biology of the Ewing's sarcoma/primitive neuroectodermal tumor family. J Clin Oncol. 18:204–213. 2000. View Article : Google Scholar : PubMed/NCBI
2	Mani S, Dutta D and De BK: Primitive neuroectodermal tumor of the liver: A case report. Jpn J Clin Oncol. 40:258–262. 2010. View Article : Google Scholar : PubMed/NCBI
3	Seemayer TA, Thelmo WL, Bolande RP and Wiglesworth FW: Peripheral neuroectodermal tumors. Perspect Pediatr Pathol. 2:151–152. 1975.PubMed/NCBI
4	Parham DM, Roloson GJ, Feely M, Green DM, Bridge JA and Beckwith JB: Primary malignant neuroepithelial tumors of the kidney: A clinicopathologic analysis of 146 adult and pediatric cases from the National Wilms' Tumor Study Group Pathology Center. Am J Surg Pathol. 25:133–146. 2001. View Article : Google Scholar : PubMed/NCBI
5	Thyavihally YB, Tongaonkar HB, Gupta S, Kurkure PA, Amare P, Muckaden MA and Desai SB: Primitive neuroectodermal tumor of the kidney: A single institute series of 16 patients. Urology. 71:292–296. 2008. View Article : Google Scholar : PubMed/NCBI
6	Chu WC, Reznikov B, Lee EY, Grant RM, Cheng FW and Babyn P: Primitive neuroectodermal tumour (PNET) of the kidney: A rare renal tumour in adolescents with seemingly characteristic radiological features. Pediatr Radiol. 38:1089–1094. 2008. View Article : Google Scholar : PubMed/NCBI
7	Kim JS, Chung IS, Lim SH, Park Y, Park MJ, Kim JY, Kim YG, Hong JT, Kim Y and Han SB: Preclinical and clinical studies on cytokine-induced killer cells for the treatment of renal cell carcinoma. Arch Pharm Res. 37:559–566. 2014. View Article : Google Scholar : PubMed/NCBI
8	Li H, Yu JP, Cao S, Wei F, Zhang P, An XM, Huang ZT and Ren XB: CD4+CD25+ regulatory T cells decreased the antitumor activity of cytokine-induced killer (CIK) cells of lung cancer patients. J Clin Immunol. 27:317–326. 2007. View Article : Google Scholar : PubMed/NCBI
9	Liu L, Zhang W, Qi X, Li H, Yu J, Wei S, Hao X and Ren X: Randomized study of autologous cytokine-induced killer cell immunotherapy in metastatic renal carcinoma. Clin Cancer Res. 18:1751–1759. 2012. View Article : Google Scholar : PubMed/NCBI
10	Bartholow T and Parwani A: Renal primitive neuroectodermal tumors. Arch Pathol Lab Med. 136:686–690. 2012. View Article : Google Scholar : PubMed/NCBI
11	Ellinger J, Bastian PJ, Hauser S, Biermann K and Müller SC: Primitive neuroectodermal tumor: Rare, highly aggressive differential diagnosis in urologic malignancies. Urology. 68:257–262. 2006. View Article : Google Scholar : PubMed/NCBI
12	Lam JS, Hensle TW, Delbelenko L, Granowetter L and Tennenbaum SY: Organ confined primitive neuroectodermal tumour arising from the kidney. J Pediatr Surg. 38:619–621. 2003. View Article : Google Scholar : PubMed/NCBI
13	Rodríguez-Galindo C, Liu T, Krasin MJ, Wu J, Billups CA, Daw NC, Spunt SL, Rao BN, Santana VM and Navid F: Analysis of prognostic factors in ewing sarcoma family of tumors: Review of St. Jude Children's Research Hospital Studies. Cancer. 110:375–384. 2007. View Article : Google Scholar : PubMed/NCBI
14	Ellison DA, Parham DM, Bridge J and Beckwith JB: Immunohistochemistry of primary malignant neuroepithelial tumors of the kidney: A potential source of confusion? A study of 30 cases from the national Wilm's tumor study pathology center. Hum Pathol. 38:205–211. 2007. View Article : Google Scholar : PubMed/NCBI
15	Wada Y, Yamaguchi T, Kuwahara T, Sugiyama Y, Kikukawa H and Ueda S: Primitive neuroectodermal tumour of the kidney with spontaneous regression of pulmonary metastases after nephrectomy. BJU Int. 91:121–122. 2003. View Article : Google Scholar : PubMed/NCBI
16	Ravindra S and Kini U: Cytomorphology and morphometry of small round-cell tumors in the region of the kidney. Diagn Cytopathol. 32:211–216. 2005. View Article : Google Scholar : PubMed/NCBI
17	Risi E, Iacovelli R, Altavilla A, Alesini D, Palazzo A, Mosillo C, Trenta P and Cortesi E: Clinical and pathological features of primary neuroectodermal tumor/Ewing sarcoma of the kidney. Urology. 82:382–386. 2013. View Article : Google Scholar : PubMed/NCBI
18	Kumar R, Gautam U, Srinivasan R, Lal A, Sharma U, Nijhawan R and Kumar S: Primary Ewing's sarcoma/primitive neuroectodermal tumor of the kidney: Report of a case diagnosed by fine needle aspiration cytology and confirmed by immunocytochemistry and RT-PCR along with review of literature. Diagn Cytopathol. 40 Suppl 2:E156–E161. 2012. View Article : Google Scholar : PubMed/NCBI
19	Schmidt-Wolf IG, Finke S, Trojaneck B, Denkena A, Lefterova P, Schwella N, Heuft HG, Prange G, Korte M, Takeya M, et al: Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma. Br J Cancer. 81:1009–1016. 1999. View Article : Google Scholar : PubMed/NCBI
20	Jäkel CE, Hauser S, Rogenhofer S, Müller SC, Brossart P and Schmidt-Wolf IG: Clinical studies applying cytokine-induced killer cells for the treatment of renal cell carcinoma. Clin Dev Immunol. 2012:4732452012. View Article : Google Scholar : PubMed/NCBI
21	Pievani A, Borleri G, Pende D, Moretta L, Rambaldi A, Golay J and Introna M: Dual-functional capability of CD3+CD56+ CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity. Blood. 118:3301–3310. 2011. View Article : Google Scholar : PubMed/NCBI
22	Girardi M, Oppenheim DE, Steele CR, Lewis JM, Glusac E, Filler R, Hobby P, Sutton B, Tigelaar RE and Hayday AC: Regulation of cutaneous malignancy by gammadelta T cells. Science. 294:605–609. 2001. View Article : Google Scholar : PubMed/NCBI
23	Karimi M, Cao TM, Baker JA, Verneris MR, Soares L and Negrin RS: Silencing human NKG2D, DAP10 and DAP12 reduces cytotoxicity of activated CD8+ T cells and NK cells. J Immunol. 175:7819–7828. 2005. View Article : Google Scholar : PubMed/NCBI